Evolution of myeloid leukemia in children with Down syndrome

Area of Science:

• Pediatric Oncology
• Hematology
• Genetics

Background:

• Children with Down syndrome (DS) exhibit a significantly elevated risk for leukemia.
• A specific subtype, myeloid leukemia associated with DS (ML-DS), is preceded by transient abnormal myelopoiesis (TAM) in neonates.

Purpose of the Study:

• To review the evolutionary process of leukemogenesis from TAM to ML-DS in Down syndrome.
• To discuss advances in understanding perturbed hematopoiesis in DS, focusing on GATA1 mutations and cooperating genetic events.

Main Methods:

• Literature review of clinical and laboratory studies.
• Analysis of genetic alterations and epigenetic regulators involved in disease progression.

Main Results:

• Constitutional trisomy 21 and GATA1 mutations are key drivers for TAM development.
• Additional genetic alterations in epigenetic regulators and signaling molecules contribute to the progression from TAM to ML-DS.

Conclusions:

• The TAM to ML-DS progression serves as a critical model for multi-step leukemogenesis.
• Understanding these genetic events is crucial for deciphering hematopoiesis in DS and developing targeted therapies.